PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Ameya Puranik, Indraja D. Dev, Sushil Yadav, Venkatesh Rangarajan et autres
in (code pays fourni par la source)